A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

Summary

The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.

Timeline

Start

2026-07-01

Primary completion

2029-07-01

Completion

2030-01-31

Drugs

Indications